Computational discovery of novel, ip-clear actives for OTC nerve-pain relief
QENEX offers a cutting-edge AI and quantum-chemistry platform that discovers and prioritizes novel candidate actives for nerve-pain relief. This co-development opportunity allows partners to validate de-risked, IP-clear candidates with clear mechanism-to-outcome links, ensuring OTC-suitable safety and efficacy.
Overview
QENEX has developed an innovative AI and quantum-chemistry platform designed to discover and computationally prioritize novel candidate actives for nerve-pain relief. The platform focuses on creating molecules that target validated nociceptive mechanisms such as Nav1.7/1.8 sodium channels, TRPV1/TRPM8, and KCNQ. This approach generates candidates with predicted potency, selectivity, and OTC-appropriate ADMET/tolerability before synthesis, offering a unique advantage in developing differentiated, freedom-to-operate-clean candidates beyond traditional options like alpha-lipoic acid.
Technical specifications
Key features:
- AI-driven platform integrates quantum chemistry for precise molecule design
- Targets multiple mechanisms including Nav1.7/1.8 sodium channels, TRPV1/TRPM8, and KCNQ
- Predicts potency, selectivity, and ADMET/tolerability in silico
- Provides a stage-gated process for candidate discovery and validation
- IP-clear candidates ready for co-development and validation
Technology readiness level
This platform is at Technology Readiness Level 6, indicating a fully functional prototype with demonstrated capabilities in relevant environments. The platform is poised for collaborative development, where partners can validate the candidates through wet-lab assays and integration into consumer pipelines.
About QENEX LTD
QENEX LTD is a UK-incorporated, early-stage technology company focused on quantum computing, quantum chemistry, and post-quantum cryptography. The firm operates as an unregulated B2B software developer, providing platforms such as QENEX Lab, which enables cryptographic provenance for research outputs. By anchoring legal artifacts, scan results, and research data to public blockchains and IPFS using cryptographic chains, the company offers an independently verifiable alternative to traditional certifications. The codebase is primarily sole-authored by the founder, with development efforts currently centered on self-hosted infrastructure and research-oriented software solutions.
This approach to verifiable, evidence-based transparency serves researchers and organizations that require high levels of integrity for their digital artifacts. By leveraging technologies like Ed25519-signed receipts and RFC 3161 qualified timestamps, QENEX helps users establish a transparent audit trail for their work. The company maintains an open posture, documenting its security practices and corporate status through a public-facing Trust Centre, which provides stakeholders with the ability to independently verify the company's activities without reliance on proprietary black-box systems.
delivered to your inbox.